NSE - Delayed Quote INR

AKUMS DRUGS AND PHARMA L (AKUMS.NS)

Compare
618.25
+0.85
+(0.14%)
At close: January 10 at 3:29:54 PM GMT+5:30
Loading Chart for AKUMS.NS
DELL
  • Previous Close 617.40
  • Open 617.95
  • Bid --
  • Ask --
  • Day's Range 605.50 - 632.40
  • 52 Week Range 530.05 - 1,175.90
  • Volume 465,894
  • Avg. Volume 408,300
  • Market Cap (intraday) 94.655B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 33.44
  • EPS (TTM) 18.49
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 840.00

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company. It also sells branded pharmaceutical formulations. The company was incorporated in 2004 and is based in Delhi, India.

www.akums.in

7,388

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AKUMS.NS

View More

Performance Overview: AKUMS.NS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

AKUMS.NS
4.18%
S&P BSE SENSEX
1.11%

1-Year Return

AKUMS.NS
14.72%
S&P BSE SENSEX
8.39%

3-Year Return

AKUMS.NS
14.72%
S&P BSE SENSEX
29.52%

5-Year Return

AKUMS.NS
14.72%
S&P BSE SENSEX
86.67%

Compare To: AKUMS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AKUMS.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    94.52B

  • Enterprise Value

    91.58B

  • Trailing P/E

    33.50

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.41

  • Price/Book (mrq)

    3.34

  • Enterprise Value/Revenue

    2.34

  • Enterprise Value/EBITDA

    23.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.80%

  • Return on Assets (ttm)

    5.01%

  • Return on Equity (ttm)

    16.60%

  • Revenue (ttm)

    40.83B

  • Net Income Avi to Common (ttm)

    2.78B

  • Diluted EPS (ttm)

    18.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.95B

  • Total Debt/Equity (mrq)

    18.63%

  • Levered Free Cash Flow (ttm)

    607.29M

Research Analysis: AKUMS.NS

View More

People Also Watch